Minireviews
Copyright ©The Author(s) 2016.
World J Gastrointest Endosc. Feb 10, 2016; 8(3): 165-172
Published online Feb 10, 2016. doi: 10.4253/wjge.v8.i3.165
Table 1 Characteristics and main results of two reviews
ReviewYearStudy type
Primary tumor
Procedure
Favorable groupregarding several variables
RetroProRCTStomachPancreasOthersGJESToleration of oral intake1Time to oral intake2(d)Hospital stay3(d)Complication
12010101294 (18.3%)240 (46.7%)180 (35.0%)255 (LGJ 37)244ESES (2.0 d)ES (9.4 d)GJ is approximately equal to ES
2201203355 (28.6%)86 (44.8%)51 (26.6%)92 (LGJ 0)74GJ (not-RCT)ES (2.1-5.0 d)ES (2.5-7.0 d)Major: GJ is approximately equal to ES Minor: ES
Table 2 Patient demographics and main results in two reviews
Ref.Study typeProcedure
Performance status
Comparison between GJ and ESregarding several variables
GJESGJESToleration of oral intakeGOO recurrenceTime to oral intakeHospital stayComplication
Fiori et al[53]Prospective9 (LGJ 0)9NRNRGJ is approximately equal to ESGJ (0%) < ES (33%)aGJ (6.3 d)GJ (10 d)GJ: SSI, bleeding, ventral hernia
ES (3.1 d)ES (4.8 d)ES: Stent dislocation, re-obstruction
No et al[54]Retrospective41 (LGJ 9)720-11: 68.3%0-11: 59.7%GJ (95.1%) is approximately equal to ES (87.5%)GJ (12.2%) < ES (44.4%)aGJ (16 d) > ES (10 d)aGJ (18 d) > ES (16 d)3GJ is approximately equal to ES
21: 31.7%21: 40.3%
Keränen et al[55]Retrospective21 (LGJ 0)50I-II2: 90.5%I-II2: 58%GJ (81%) is approximately equal to ES (88%)GJ (9.5%)GJ (4 d) > ES (1 d)aGJ (8 d) > ES (3 d)aGJ (10%)
III-IV2: 9.5%III-IV2: 42%ES (24%)ES (26%)